Skip to main content
. Author manuscript; available in PMC: 2013 May 19.
Published in final edited form as: AIDS. 2011 Sep 10;25(14):1779–1787. doi: 10.1097/QAD.0b013e328349f067

Figure 1. Cost-Effectiveness of Testing for & Treating Acute HIV Infection.

Figure 1

Incremental costs and quality-adjusted life years (QALYs) are plotted for each strategy of testing for HIV infection, with the origin corresponding to the status quo. Under each strategy, 50% of individuals identified as acutely infected receive antiretroviral therapy (ART) for the duration of their acute infection. The solid lines show the incremental cost-effectiveness ratio (ICER) relative to the next-best alternative. The dashed lines show the ICER relative to the next-best alternative if increasing annual screening coverage is infeasible. Although these strategies are dominated by similar strategies with expanded annual screening coverage, they are relevant if increasing screening coverage is infeasible. Incremental costs and QALYs are calculated over a 20-year time horizon and are discounted to the present at 3% annually.

Note: Ab = antibody, VL = viral load, Symptom-based = 35% of symptomatic acutely infected MSM receive Ab & VL testing.